Stock Analysis
Chugai Pharmaceutical First Quarter 2024 Earnings: Misses Expectations
Chugai Pharmaceutical (TSE:4519) First Quarter 2024 Results
Key Financial Results
- Revenue: JP¥236.9b (down 24% from 1Q 2023).
- Net income: JP¥74.4b (up 1.2% from 1Q 2023).
- Profit margin: 31% (up from 24% in 1Q 2023). The increase in margin was driven by lower expenses.
- EPS: JP¥45.22 (up from JP¥44.68 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Chugai Pharmaceutical Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 4.1%.
Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan.
Performance of the Japanese Pharmaceuticals industry.
The company's shares are down 4.5% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Chugai Pharmaceutical that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Chugai Pharmaceutical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4519
Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
Flawless balance sheet with proven track record and pays a dividend.